Observational studyBMJ open respiratory research2026
Resource impact of bronchiectasis and associated exacerbations: based on a 5-year prospective observational cohort study (BronchUK).
Observational study in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur objective is to document major healthcare resource use and associated costs in the care of patients with bronchiectasis, with a particular focus on the costs incurred by exacerbations.
methodsWe use a unique dataset from the Bronchiectasis Observational Cohort and Biobank UK. The study includes a baseline cohort of 1119 patients with a primary diagnosis of bronchiectasis, followed for up to five years. Data were extracted and linked to centrally held National Health Service (NHS) resource use data.
resultsThe average age of the cohort was 64 years and 62% were female. The most common bronchiectasis aetiology was idiopathic or post-infectious. Across follow-ups, exacerbations became less frequent: the proportion of patients with no events increased for all settings, while recurrent (≥2) events declined markedly and single-event categories remained largely stable. Exacerbations were predominantly managed in primary care settings. Based on exacerbation frequency and type and applying 2024/2025 NHS reference costs, the estimated total healthcare exacerbation costs for the study population ranged from £2 million to £3.2 million. Disaggregated estimates for the highest cost scenario include: general practitioner (GP)-only exacerbations (n=2824 events; £479 945), emergency department-managed exacerbations (n=311; £260 126) and inpatient-managed exacerbations (n=680; £2 428 291). The average estimated cost per patient over the full period was £1943. This corresponds to a weighted annual average of £495 per patient (including patients with no exacerbations), with most costs attributable to inpatient-managed exacerbations. Specifically, the average cost was £2980 for individuals with one or more exacerbations, £4865 for those with two or more and £5875 for those with three or more.
conclusionsThe findings highlight the economic burden of bronchiectasis exacerbations and demonstrate that targeted management strategies to reduce exacerbation rates should increase health benefits and substantially reduce healthcare costs associated with bronchiectasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.